Table 2.
Chemotherapy treatment patterns
| Chemotherapy regimen | Abbreviation | Number | Dose delays ≥7 days n (%) |
RDI ≤85% n (%) |
Switched regimen n (%) |
|---|---|---|---|---|---|
| Breast cancer | 3314 | 307 (9.3) | 840 (25.3) | 186 (5.6) | |
| Doxorubicin + cyclophosphamide | AC | 352 | 14 (4.0) | 37 (10.5) | 12 (3.4) |
| AC followed by paclitaxel or docetaxel | AC-T | 633 | 85 (13.4) | 451 (71.2) | 6 (0.9) |
| Dose-dense AC-T | ddAC-T | 293 | 61 (20.8) | 99 (33.8) | 4 (1.4) |
| Cyclophosphamide + docetaxel | TC | 814 | 38 (4.7) | 74 (9.1) | 50 (6.1) |
| Docetaxel + doxorubicin + cyclophosphamide | TAC | 423 | 40 (9.5) | 42 (9.9) | 22 (5.2) |
| Cyclophosphamide + doxorubicin + fluorouracil | CAF | 148 | 9 (6.1) | 10 (6.8) | 7 (4.7) |
| Trastuzumab + AC-T | -- | 187 | 25 (13.4) | 112 (59.9) | 19 (10.2) |
| Docetaxel + carboplatin + trastuzumab | TCH | 464 | 35 (7.5) | 15 (3.2) | 66 (14.2) |
| Lung cancer | 1443 | 161 (11.2) | 259 (17.9) | 227 (15.7) | |
| Etoposide + carboplatin | EC | 187 | 43 (23.0) | 56 (29.9) | 26 (13.9) |
| Gemcitabine + carboplatin | G/C | 180 | 31 (17.2) | 42 (23.3) | 39 (21.7) |
| Carboplatin + paclitaxel | NA | 878 | 79 (9.0) | 134 (15.3) | 158 (18.0) |
| Etoposide + cisplatin | EP | 198 | 8 (4.0) | 27 (13.6) | 4 (2.0) |
| NHL | 581 | 96 (16.5) | 162 (27.9) | 38 (6.5) | |
| Cyclophosphamide + doxorubicin + vincristine + prednisone | CHOP | 60 | 8 (13.3) | 24 (40.0) | 5 (8.3) |
| Rituximab + CHOP | R-CHOP | 521 | 88 (16.9) | 138 (26.5) | 33 (6.3) |